Off-Label Promotion: Record-High Settlements Have the FDA and DOJ Wanting More

Quantity Discounts
1 - 9999
1 - 9999
1 - 9999
ALERT: Fines and settlements are at an all-time high for off-label violations … the federal government has collected nearly $12 billion in fines by prosecuting healthcare fraud over the past 10 years.

HURRY, this event is taking place very soon!

The Justice Department is working on more than 200 investigations — involving up to 500 products — of pharmaceutical companies for alleged off-label violations. The government is broadening its enforcement efforts and is focusing on small companies, even “pure” off-label cases where there is no evidence of kickbacks or harm to Medicare or Medicaid.

To make matters even more confusing, the FDA has issued new rules allowing companies to distribute off-label information in medical journals even though the articles may promote product usage not approved by the agency.

How can you minimize the risk of being investigated, facing mammoth fines and losing your right to sell to Medicare for an off-label promotion violation?

Sign up now for this 90-minute Encore presentation led by noted attorney Alan Minsk and listen in as he examines the numerous laws that apply to off-label promotion. He will explain the issues to consider when interacting with healthcare professionals and will detail strategies to address and minimize the risk of these violations.

Sign up your entire team to listen in and discover:

  • How to minimize the risk of a government investigation into sales and marketing practices
  • A no-nonsense explanation of what off-label promotion is and what it is not
  • How to navigate the latest rules on distributing information via medical journals
  • How the False Claims Act, anti-kickback laws, PDMA and other laws relate to off-label marketing
  • What the “red flags” are for government enforcement — gleaned from recent court decisions and prosecutions
  • The threat of qui tam actions and how to prevent them
  • Best practices for ensuring that interactions with healthcare professionals are fully compliant — what you should and shouldn’t say 

Have the strategies in place to help avoid huge fines, criminal prosecution or other penalties — register now! You’ll get a chance to ask your toughest questions during the Q&A session.

This presentation is a must for positions in drug, biotech, biologic, device and diagnostics companies, including:
  • Compliance officers
  • Executive management
  • General/corporate counsel
  • Regulatory/legislative affairs professionals
  • Risk management specialists
  • Sales and marketing personnel
  • Training personnel
  • Medical science liaisons
  • Outside attorneys

Alan Minsk is partner and chair of the Food & Drug Practice Team of Arnall Golden Gregory LLP. He advises pharmaceutical and medical device companies on all legal and regulatory matters relating to the FDA and certain matters concerning numerous other governmental agencies. Alan counsels, speaks and writes on a wide variety of FDA-related issues, including product promotion and advertising, FDA enforcement, market exclusivity, FDA inspections, regulatory strategy and life cycle management and much more.

Register now!

Date: May 25 – June 12, 2009
Location: Your office or conference room (no need to travel!)
Time: Anytime

Gather your team for maximum benefit! Your investment is for one dial-in.

Interested in registering multiple sites?
Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally
to learn about our special multisite discount.

We accept American Express, Visa and MasterCard. Make checks payable to FDAnews.

Or, register by phone: toll free (888) 838-5578 (inside the U.S.) or +1 (703) 538-7600

Registrations may not be cancelled. Please contact customer service to make any substitutions.

Interested in Becoming a Speaker?
We're always looking for industry leaders eager to share their expertise at an FDAnews audioconference, webinar or physical conference. Our seasoned speaker community includes executives in the pharmaceutical, medical device and clinical trial industries, regulatory affairs, quality control, compliance, healthcare and academia, as well as several former — and current — top FDA officials. Click here to complete our speaker opportunity form and have a representative contact you about future opportunities.